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Abstract: Repeat episodes of HPV-related external genital warts reflect recurring or new 
infections. No study before has been sufficiently powered to delineate how tobacco use, 
prior history of EGWs and HIV infection affect the risk for new EGWs. Behavioral, 
laboratory and examination data for 2,835 Multicenter AIDS Cohort Study participants 
examined at 21,519 semi-annual visits were evaluated. Fourteen percent (391/2835) of 
men reported or were diagnosed with EGWs at 3% (675/21,519) of study visits. 
Multivariate analyses showed smoking, prior episodes of EGWs, HIV infection and CD4+ 
T-lymphocyte count among the infected, each differentially influenced the risk for new 
EGWs. 
Keywords: Smoking/tobacco; Genital warts; Human papillomavirus (HPV); HIV; men 
who have sex with men (MSM); CD4+ T-lymphocyte count; longitudinal/cohort. 
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1. Introduction 
 
External genital warts (EGWs) occur on the penis, scrotum, external anus, perigenital and perianal 
regions, and are largely due to infection by low-risk Human papillomaviruses (HPV) that can be 
transmitted between sexual partners [1]. Reports are not uniformly supportive in women [2,3], though 
epidemiologic studies suggest smokers are at higher risk than non-smokers for developing genital 
warts [4], abnormal cervical cytology [5-7], cervical intraepithelial neoplasia grade 3 or cervical 
cancer [7-9], and persistent HPV infection [10]. 
Early observations supported an association between HIV infection, smoking, HPV-related 
dysplasias, and specific sexual behaviors [11-22]. Several other factors may modify the influence that 
smoking has upon the natural history of EGWs. Data suggest low CD4+ T-lymphocyte count and 
higher serum HIV RNA concentrations heighten the risk for both prevalent and incident HPV 
infections [23]. However, no study before has been sufficiently powered to determine how tobacco 
use, prior history of external genital warts and human immunodeficiency virus (HIV) infection affect 
the risk for new EGWs, much less how they may interact to cause disease in men. 
Exposures that affect EGWs in men likely have bearing on other HPV-related anogenital lesions, 
e.g., intra-anal infections and anal cancer, especially in the immunocompromised. Some studies report 
anal warts are associated with a 3- to 5-fold increased risk for anal intraepithelial neoplasia (AIN) in 
HIV-infected men [24,25] Although EGWs themselves are rarely associated with cancer, their 
treatment requires significant health-care resources. U.S. insurance data suggest EGWs may cost $150 
million annually, that 25 to 34 year old men seek treatment most often and that three visits per episode 
are required before clearance is achieved [26]. It has been generally accepted that most HPV infections 
are cleared and that a fraction of cases become persistent. On average, EGWs regress within twelve 
months of detection [26-28]. Our findings and other studies support that host transcriptional regulation 
may facilitate viral latency, though the model has not been fully characterized to date [29-33]. Thus, 
understanding the factors that affect risk for EGWs has importance for basic science and clinical 
practice, resource planning, and health education efforts. 
A latent HPV reservoir has not been identified, and it is unclear how prior EGWs influence the risk 
for recurrence. Recent data by Strickler et al., show that among HIV-infected women, HPV disease 
recurs in the absence of sexual contact with a partner [23], an indication that recrudescent disease may 
play a role for some individuals. If we assume that infections are generally self-limiting, controlling 
for the effect of prior EGWs may introduce bias into our analyses by controlling for the effect of an 
intermediate variable [34]. Instead, although we hypothesize that infections are recurrent, we cannot 
discriminate recurrent from new infections in these data. Thus, we estimated the effect of prior 
episodes of warts to determine whether they influenced the risk for later recurrence or new EGW 
occurrences. To understand how smoking, HIV infection, CD4+ T-lymphocyte cell counts, and 
historical EGWs jointly affect the risk for new EGWs, we studied demographic, behavioral, laboratory 
and physical examination data gathered over as many as nine semi-annual visits from 2,835 gay, 
bisexual, transgender, and other men who have sex with men (MSM).  
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2. Results 
 
Descriptive statistics: About three-quarters of men we studied completed seven to nine MACS study 
visits (76%, 2,167/2,835). Data were gathered at 7,315 visits where men were HIV-infected and at 
14,204 visits where men tested HIV negative. HIV infection is a time dependent covariate; of the 
infected, 808 men were infected at the first visit (seroprevalent) and 280 became infected between their 
first and last MACS visit (seroconverters). A total of 1,747 men that tested persistently HIV-negative 
were included in these analyses.  
Smoking, HIV infection characteristics, and a prior history of warts were related in these analyses. 
Approximately 25% of the study group reported ever smoking across the study period. Additionally, 
more than half were unaffected, never having shown evidence of EGWs during the first 16 MACS 
visits and reporting no episodes of EGWs during the two years prior to enrollment in the MACS 
(Table 1). About 60% of HIV-infected men showed at least one study visit where the CD4+ T-
lymphocyte count was at least 500 cells/mm
3 
and nearly as many showed no visits where counts fell 
below 200 cells/mm
3
 (Table 1).  
Smokers were 23% more likely than non-smokers to have shown or reported historical incidence of 
EGWs [risk ratio (RR) = 1.2, (1.2, 1.3)]; also, HIV-infected men more often smoked [RR = 1.2, (1.1, 
1.3)] and showed a history of EGWs [RR = 1.9 (1.8, 2.0)] when compared to uninfected men. 
Additionally, historical evidence of EGWs and CD4+ cell count were associated among HIV infected 
individuals. For example, men with 200 or fewer CD4+ cells/mm
3
 were more than twice as likely as 
men with higher CD4+ cell counts to have entered the risk period with a history of EGWs (RR = 2.5, 
(2.3, 2.9)).  
Incident EGWs were reported or diagnosed by MACS examiners for 14% (391/2,835) of men at 3% 
(675/21,519) of study visits. Nearly half of EGWs were diagnosed by examiners alone (52%, 
348/675), 16% (108/675) were reported by participants and confirmed on examination, and 32% 
(219/675) were reported by participants only. Nearly three-quarters (78%, 357/456) of incident warts 
were diagnosed on anal/perianal surfaces. On average, the average rate of warts diagnosed or reported 
annually was 0.07 visits/year (Table 1). 
 
Multivariate analyses: Our iterative models showed incident EGWs were associated with smoking, 
historical EGWs, and HIV infection characteristics, including CD4+ cell count in these data (Table 2). 
The risk for incident EGWs increased only about 2% with each receptive anal partnership and did not 
change appreciably for each insertive partnership, i.e., RR = 1.02, (1.00, 1.04) and RR = 1.0, (0.99, 
1.01), respectively (Table 2). Further, when we controlled for the potential confounding effects of age, 
partner number, education, time on study, MACS visit sequence, and repeated observations, the 
relative risk for EGWs was influenced by smoking, history of EGWs, HIV-infection status and CD4+ 
cell count (Tables 2 & 3). Our estimates suggest a synergistic relationship between the four latter 
characteristics. Also, estimates of the risk ratio improved marginally when behavioral and 
sociodemographic characteristics, repeated measurements, and the order of study visits were 
incorporated iteratively into the model (Models 1-5, Table 2). For example, when we adjusted for the 
effect of repeated measurements within subjects and the order of study visits alone in the initial 
multivariate analysis, men who smoked were 20% more likely to be diagnosed with EGWs than were Int. J. Environ. Res. Public Health 2009, 6   
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non-smokers, compared to the 40% inferred in the crude analysis, i.e., crude RR = 1.4 (1.2, 1.7); 
adjusted RR 1.2 (1.1, 1.5) respectively. 
Table 1. Smoking, HIV- and EGW-related characteristics of 2,835 MultiCenter AIDS 
Cohort Study Participants. 
 
 
 
 
Characteristic N  (%) 
Smoking  
Never smoked  2,087 (74)
Ever Smokers  748 (26)
 
Number of Visits Where EGWs were Reported or Diagnosed Among Men Who Reported 
Never Having Had EGWs Before the First MACS visit  
0 wart visits  1,805 (64)
1   126 ( 4)
>2 77  (<3)
Ever Having Had EGWs Before the First MACS visit    
0 wart visits  639 (23)
1  117 ( 4)
>2 71  (<3)
HIV Infected Men 
Number of Visits CD4+ T-lymphocytes < 200 cells/mm
3 a
 
0 visits  668 (61)
1-3 245  (23)
4-9 175  (16)
Number of Visits CD4+ T-lymphocytes > 500 cells/mm
3 a
 
0 visits  421 (39)
1-3 292  (27)
4-9 375  (34)
Visits Where EGWs Were Reported Or Detected Over the Study Period 
Mean (SD)  0.24 (+0.75 SD)
Median   0
EGW-positive visits per year   
Mean (SD)  0.07/year
Median   0/year
a HIV-infected men only, N = 1,088 (%)  Int. J. Environ. Res. Public Health 2009, 6   
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Table 2. Comparison of Five Multivariate Analyses of Relationships Between Behavioral 
and Demographic Characteristics and Incident EGWs for 21,519 Semi-Annual Study 
Visits, Adjusted for the Effect Of Repeated Measurements. Adjusted Risk Ratios were 
Derived from Maximum-Likelihood Logistic Regression Using Generalized Linear Models 
with Repeated Binary Responses (95% Confidence Limits). 
 Characteristic  Number 
of Visits 
Number of 
visits EGWs 
reported or 
Examiner 
Diagnosed  
N (% row) 
Risk Ratio (95% Confidence Limits)
 1 
Model 1
1  Model 2
1  Model 3
1 Model  4
1 Model  5
1 
Smoking 
Smokers  5,888  232 (4)  1.2  
(1.0, 1.4) 
1.2  
(1.0, 1.4) 
1.2  
(1.0, 1.4) 
1.2  
(1.0, 1.4) 
1.2  
(1.0, 1.4) 
Non-smokers  15,631  443  (3)  1  1  1 1 1 
History of EGWs 
Yes  6,253  320 (5)  2.0  
(1.6, 2.5) 
1.9  
(1.5, 2.5) 
2.0  
(1.6, 2.5) 
2.0  
(1.6, 2.5) 
2.0  
(1.5, 2.5) 
No  15,266  355  (2)  1  1  1 1 1 
HIV Infection Status 
HIV Negative  14,204  291 (2)  1
2 1
2 1
2 1
2 1
2 
HIV Infected       2.2  
(1.8, 2.8)
3 
     
> 850 CD4+ cells  729  27 (4)    2.1  
(1.3, 3.4) 
2.0  
(1.3, 3.3) 
2.0  
(1.3, 3.3) 
2.1  
(1.3, 3.3) 
500-849  2,202  118 (5)    2.4  
(1.8, 3.2) 
2.3  
(1.8, 3.1) 
2.3  
(1.8, 3.1) 
2.2  
(1.7, 3.0) 
350-499 1,592  70  (4)    2.2   
(1.6, 2.9) 
2.1  
(1.6, 2.9) 
2.1  
(1.3, 3.5) 
2.0  
(1.5, 2.8) 
200-349 1,414  78  (5)    2.4   
(1.7, 3.3) 
2.4  
(1.7, 3.4) 
2.4  
(1.8, 3.4) 
2.3  
(1.7, 3.3) 
< 200  1,378  91 (7)    2.8  
(2.0, 4.0) 
2.7  
(1.9, 3.9) 
2.7  
(1.9, 3.8) 
2.6  
(1.8, 3.7) 
Number RAI 
Partners during last 
6 months
4  
       1.02  
(1.00, 1.03) 
1.02  
(1.00, 1.04) 
1.02  
(1.00, 1.04) 
Number IAI 
Partners during last 
6 months
5 
       1.00  
(0.99, 1.02) 
1.00  
(0.99, 1.01) 
1.00  
(0.99, 1.01) 
Time on study
6         1.00   
(1.00, 1.00) 
1.00  
(1.00, 1.00) 
1.00  
(1.00, 1.00) 
Age
7         0.99   
(0.97, 1.00) 
0.99  
(0.97, 1.01) 
0.99  
(0.97, 1.01) 
Education: 
< 12
th grade  2090  85 (4)        1.4  
(0.9, 2.2) 
1.4 
(0.9, 2.2) 
Some  College 5406  169  (3)      1.0   
(0.7, 1.5) 
1.0 
(0.7, 1.4) 
Baccalaureate 
Graduate 
5521  189  (3)      1.3   
(0.9, 1.8) 
1.3 
(0.9, 1.7) 
Some Post-graduate 
Education 
2886  94  (3)      1.2  (0.8, 
1.8) 
1.1 (0.7, 
1.7) 
Post-graduate 
Degree 
5616  138  (2)      1  1 Int. J. Environ. Res. Public Health 2009, 6   
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Table 2. Cont. 
1  Adjusted for the effect of repeated measurements for 2,835 subjects and order of semi-annual 
study visits; 
2 Referent group in HIV comparisons; 
3 Comparison for HIV infection status, not 
stratified by CD4+ cell count (cells/mm
3); 
4 Number of “receptive anal intercourse partners” was 
entered into the model as a single, continuous variable; 
5    Number of “insertive anal intercourse 
partners” was entered into the model as a single, continuous variable; 
6  Time on study was 
entered into the model as the number of days since first MACS visit, as a single, continuous 
variable; 
7 Age, in years, was subtracted from the mean age of the population and entered as a 
single, continuous variable. 
Table 3. Multivariate Relationship Between Smoking, Prior History of Genital Warts, 
HIV-Infection Status and CD4+ Cell Count and Risk for New EGWs, Adjusted for the 
Effect of Behavioral and Demographic Characteristics. Adjusted Risk Ratios were Derived 
from Maximum-Likelihood Logistic Regression Analysis Using Generalized Linear 
Models with Repeated Binary Responses (95% Confidence Limits). 
 
HIV 
Uninfected  
HIV Infected 
CD4+ Cell Count 
>850   500 – 849  350 - 499  200 - 349  < 200 
Risk Ratios (95% Confidence Limits) 
No History of EGWs 
Non-smokers
a   1  2.1  
(1.4, 2.1) 
2.5  
(1.7, 3.7) 
2.1  
(1.5, 3.1)
b 
1.9  
(1.3, 2.8)  3.2 (2.2, 4.7)
b 
Smokers
a   1.0  
(0.7, 1.5)
c 
2.7  
(1.9, 3.9)
c 
2.0  
(1.3, 2.9)
c 
3.9  
(2.6, 5.7)
b, c 
3.1  
(2.1, 4.6)
c 
3.8 (2.6, 5.6)
b, 
c 
Prior History of EGWs 
Non Smokers
a   2.3  
(1.6, 3.4)
b 
1.4  
(1.0, 3.0) 
3.9  
(2.7, 5.8)
b 
2.7  
(1.8, 4.0)
b 
4.4  
(3.0, 6.5)
b  3.9 (2.1, 7.1)
b 
Smokers
a   2.4  
(1.5, 3.9)
b, c 
8.9  
(6.0, 13.1)
c 
7.1  
(4.8, 10.4)
b, c 
5.1  
(3.4, 7.5)
b, c 
7.4  
(5.0, 10.9)
b, c 
6.9 (4.7, 
10.1)
b, c 
a Multivariate Risk Ratios are adjusted for the effect of smoking, history of EGWs, HIV infection status, and for 
the infected, CD4+ cell count, number of receptive- and insertive-anal sex partnerships, and time on study 
reported at each study visit, and for age centered about the mean of the study group, education, study site, 
repeated measures (within subject variation), and MACS visit sequence; 
b For each column, statistical contrasts 
are of shaded versus unshaded within the two “History of EGW” categories. Comparing risk ratios of smokers 
versus non-smokers, summarizing statistical contrasts of risk ratios for men with and without history of EGWs, 
stratified by HIV infection status and, among the infected, CD4+ cell count. Statistically significant associations 
shown where, correcting  for 17 statistical contrasts, p<0.003 (for each column, statistical contrasts are of 
shaded versus unshaded within the two “History of EGW” categories); 
c For smokers only, statistical contrasts 
are of unshaded rows between “History of EGW” categories. Comparing risk ratios of groups of men with and 
without warts, summarizing contrasts of risk ratios for smokers, stratified by HIV infection status and, among 
the infected, CD4+ cell count. Statistically significant associations shown where, correcting  for 17 statistical 
contrasts, p<0.003. 
Study Site 
A  5981  139  (2)       0.6 
(0.5, 0.9) 
B  4454  134  (3)       1.4 
(1.0, 2.0) 
C  4518  123  (3)       1.2 
(0.9, 1.7) 
D  6566  279  (4)        1 Int. J. Environ. Res. Public Health 2009, 6          
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Other characteristics also affected risk for new EGWs. For every year on study, our analyses 
suggested that the risk for developing new EGWs increased by about 30% (i.e., for each day on study: 
B = 0.0007, SE = 0.0001), and it increased about 2% (0.99, 1.03) for every ten years of age. Risk for 
new EGWs did not vary by educational status (i.e., compared to men who completed graduate 
education, [aRR = 1.4 (0.9, 2.2), 1.0 (0.7, 1.4), 1.3 (0.9, 1.7), 1.1 (0.7, 1.7)] for men with <12 years, 
some college education, college graduates, and men with some post-graduate education, respectively; 
Table 2). Last, we observed a 1% increased risk was associated with each receptive anal intercourse 
partnership [aRR = 1.02 (0.99, 1.03)] and for insertive anal partnerships, we saw no change in risk 
[aRR = 1.0, (0.98, 1.02); Table 2]. 
 
Multivariate Analyses with Statistical Interactions: Our primary interests were to determine how 
smoking influenced risk for new diagnoses of warts, and whether there was evidence to support 
recurring or newly occurring infection in these men. Our analyses suggested our risk ratios varied 
when the statistical interaction between smoking, history of EGWs, and HIV infection characteristics, 
including CD4+ T-lymphocyte count among the infected, were considered together (Table 3). 
Specifically, among HIV-uninfected men with no prior history of warts, we found smokers were no 
more likely than non-smokers to develop new EGWs. However, in 8 of 12 statistical contrasts, there 
was significantly greater risk for smokers than non-smokers, even after we controlled for the effect of 
other covariates (Table 3, Models 1-5, comparison of rows 1 vs. 2, and 3 vs. 4). Smoking was most 
often a significant predictor where men showed a history of prior EGWs; however, for men without a 
history of warts, these relations were most consistent for HIV-infected men with low CD4+ cell counts 
(Table 3, footnote comparisons “b”). In these comparisons, we may lack sufficient power to detect a 
statistically significant difference between risk ratios after we corrected our p-values for multiple 
contrasts, e.g., for HIV+ men with 200-349 CD4+ cell count, comparing RR = 3.1 vs. 1.9, p = 0.01 
(Table 3, row 1-2, column 5). Strikingly, risk for new EGWs was greater for men with a prior history 
of warts. This relationship held irrespective of HIV infection status and CD4+ cell count; e.g., 
comparing HIV-uninfected smokers with and without a history of EGWs, RR = 2.4 vs. 1.0 (Table 3, 
rows 2 and 4, columns 1, contrasts “c”). 
 
Sensitivity Analysis: Last, we performed a post-hoc analysis where men with self-report for EGWs that 
were not confirmed by examination were reclassified as unaffected to test whether our inferences 
might change. This analysis method showed point estimates for the risk ratios of main effects were 
nearly equal those shown in Model 5, Table 3. Although the confidence intervals for main effects were 
narrower when self-reports alone were classified as unaffected, the analyses lacked the power to detect 
statistical interactions between two or more variables. 
 
3. Discussion 
 
Although the literature is replete with findings that tobacco smoking is deleterious to human health, 
few observational studies have been statistically powered to explore these relations as they pertain to 
HPV-related outcomes in men, and none have examined how smoking interacts with other biological 
characteristics previously reported as important cofactors for HPV-related outcomes. Specifically, Int. J. Environ. Res. Public Health 2009, 6   
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these analyses suggest that smoking, historical occurrences of EGWs, and HIV infection 
characteristics together differentially influence the risk for new occurrences of genital warts. Further, 
our analyses show that these relationships are complex and that distilling them into easily understood 
patient- and provider-directives is challenging. 
Other investigators have reported positive associations between smoking, EGWs [35], and other 
HPV-related atypias. Also, others have found positive associations between smoking and persistence 
and prevalence of HPV infection in women, suggesting that our observations in men are supportive 
and consistent with prior findings [10,36]. Daily cigarette smoking and prior history of HPV infection 
are jointly associated with low-grade cervical dysplasias in women [5]. Further, women diagnosed 
with cervical cancer and high-grade neoplasias are more likely to smoke than are unaffected women 
[8,37-39]. However, some data suggest the smoking status has little influence upon risk for high-grade 
dysplasia when HPV types are simultaneously controlled for in the analyses [36,40]. Among men, 
smoking, low CD4+ cell count, anal HPV-infection and related dysplasias have been positively 
associated [41,42]. Massad et al., recently reported that both current and past female smokers were 
about 40% more likely to manifest genital warts, after controlling for the effect of HAART; and HIV 
and HPV infection, and social and behavioral characteristics [43]. 
The causal pathway that lies between smoking, HPV infection, and its associated cancers is likely 
multidimensional and complex. It is important to note that the HPVs that are associated with EGWs 
are rarely associated with malignancy. Nonetheless, smoking may affect EGW development through 
one or more metabolic pathways that are pertinent to oncogenic HPV infections: the formation of 
chemically stable DNA adducts [44], oxidation or reduction of potent tobacco-associated carcinogens 
in epithelial cells [45], modulation of inflammation-associated metaplasia or apoptotic pathways 
[46,47], by perturbing local immunity [48] and possibly, humoral responses early in HPV infection 
[49]. Also, data suggest that carcinogens inhaled through tobacco smoke can be detected in 
downstream genital organ sites [45,50,51].  
Nonetheless, some might argue that smoking is generally representative of social risk-taking 
behaviors that may differentially influencing the prevalence of HPV within sexual networks. Some 
investigators have reported associations between tobacco use and high-risk behaviors, including higher 
alcohol consumption and use of illicit drugs [52], unprotected receptive anal intercourse [53,54] and 
earlier onset of sexual debut [55]. Additionally, some cross-sectional data report smoking prevalence 
among MSMs to be double that of the general North American male population [56,57]; however, our 
estimates were more closely approximated to the U.S. mean, 21% [58]. Thus, despite the known 
biochemical and immune modulatory effects of tobacco, this study cannot rule out the contribution of 
smoking-related behavioral factors that affect HPV disease.  
Whether new EGWs found in MACS men were due to new or recrudescent HPV infections cannot 
be discerned from these data. The strong role that a history of EGWs plays in predicting new episodes 
of warts suggests recrudescence may explain some cases. In women, recurrent HPV infections among 
sexually inactive HIV-infected women suggest recrudescence occurs with some frequency in this 
population [23]. Nonetheless, recrudescence, infection with new HPV types, and persistence that 
periodically resulted in clinical warts in these data may each explain these findings. 
Epidemiological associations between HPV-related atypias and HIV infection have been reported 
consistently since early in the domestic epidemic [11-18]. Our analyses suggest that HIV infection and Int. J. Environ. Res. Public Health 2009, 6   
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immunodeficiency generally increase the risk for EGWs, which is consistent with the findings of 
others and our previously reported analyses [19,42,59,60]. Palefsky et al., observed that, while HIV-
infected men were twice as likely as uninfected men to show progression of HPV-related low-grade to 
high-grade anal dysplasias, men with fewer than 200 CD4+ cells/mm
3 were three times more likely to 
show progression than men with higher CD4+ cell counts [59]. Our data support these observations 
and suggest that these relations are further modified by the influence that historical EGWs and 
smoking have upon incident warts. For example, we found that most men with fewer than 200 CD4+ 
cells/mm
3 were two and one-half to three times more likely to develop new warts than HIV uninfected, 
non-smoking men, while the risk was nine-fold greater for smokers with historical EGWs. Although 
our findings are limited to EGWs, these relations may have bearing on other HPV-related outcomes. 
Also, our findings suggest that recrudescence may play a role in EGWs, and by extension, other 
HPV-related outcomes over time. For example, Strickler et al., recently reported that 22% of HIV-
infected women reporting no sex partnerships within at least six months of the index visit tested 
positive for HPV DNA using PCR [23]. Our analyses further support this hypothesis; when we 
performed statistical contrasts of the risk ratios across HIV and CD4+ cell count strata, men with a 
prior history of EGWs were more likely to be diagnosed with new EGWs than were men without a 
prior history of warts. 
Our investigation focuses on clinical outcomes and these data cannot speak to the underlying 
mechanisms of disease, including HPV infection characteristics. Nonetheless, experts generally agree 
that EGWs can be reliably identified by a trained examiner using bright light and magnification, and 
clinical trials show a high correlation between this diagnosis and underlying infection with non-
oncogenic HPV types (as reviewed by Beutner and Wiley [61]). Clearance of symptomatic warts is 
thought to be due to cellular immune responses. HIV infection selectively and progressively deletes 
activated antigen-specific memory T-lymphocytes that modulate these cellular immune responses. 
This may directly affect an individual’s ability to clear symptomatic warts, specifically, and genital 
HPV infections, more generally [62-70]. Other data suggest HIV infection shifts cytokine secretion 
patterns that may influence HPV as well; for example, HIV induces IL-6, a proinflammatory cytokine, 
that in turn, up-regulates transcription of HPV structural genes [71-75]. IL-6 is found in high 
concentrations in cervical cancer tissues and has been shown to up-regulate vascular endothelial 
growth factor (VEGF), and thus vascularization of neoplasias, in a dose-dependent manner [73]. Some 
HIV structural proteins also appear to up-regulate HPV RNA transcription [72]. Thus, these biological 
pathways are mechanistically supportive of the reported observations herein. 
We found a positive association between historical EGWs and new episodes of external genital 
warts. These results are consistent with our previously reported relationships between historical 
occurrences of EGWs and new occurrences of external anal warts diagnosed by trained examiners 
[19]. Persistent anogenital HPV infection among HIV-infected men and women is well documented 
[42,60,76,77]. In these analyses, we observed a two-fold increase of risk associated with historical 
evidence of prior EGWs, even among non-smoking, HIV uninfected men. This suggests, at the very 
least, that the immunological characteristics that made these men vulnerable to symptomatic warts may 
persist for some period of time. Whether the EGWs detected among these men represent new 
infections or recurrences matters little within the context of health care dollars expended for treatment 
[26]. Currently, most EGW therapies ablate the manifestations of HPV infection and do not directly Int. J. Environ. Res. Public Health 2009, 6   
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treat the infection itself [78]. Though oncogenic HPV types were not specifically studied, EGWs and 
their associated low-risk viruses may be proxy indicators of infection by cancer-causing HPV types. 
The implications of this study have clinical relevance in assessing risk factors for HPV pathogenesis, 
with the goal of directly targeting screening strategies for those most likely to be affected by HPV-
related disease. 
There are some limitations to these analyses. The MACS participants are a select group of men and 
findings based on their data may not be easily generalized to all men or to all MSM, specifically. 
Approximately one-third of the incident EGWs reported were not confirmed by a MACS examiner. 
However, prior analyses suggest that, on average, affected men are unlikely to be aware of their EGWs 
[79]. Thus, these reported occurrences may reflect diagnoses made between MACS visits by 
community clinicians. Including self-report for EGWs in addition to those diagnosed by a MACS 
examiner may have introduced information bias, such as recall or interview biases. However, using the 
more conservative classification scheme to group men with self-reported EGWs together with 
unaffected men in our post-hoc sensitivity analysis was less informative. Self-report data often cause 
misclassification, resulting in biases that are difficult to predict [80]. Also, EGWs are an observable 
clinical outcome resulting from HPV infection, and do not directly confirm the presence or absence of 
type-specific HPV DNA. The MACS has not tested for HPV nor have they gathered specimens that 
can be tested retrospectively. Thus, we cannot determine whether men with prior EGWs are more 
often exposed to HPVs, are persistently infected with particular HPV types, or are more likely to be 
symptomatic given HPV infection. Last, our inability to detect statistically significant differences 
between some contrasted groups may be related to sparsely populated cells when data were fully 
stratified. For example, data for 96 visits were available for HIV-infected smokers with 850 CD4+ 
cells/mm
3 who showed a history of EGWs, and data from 140 visits were analyzed for men who 
showed no history of EGWs but were otherwise similar. It is likely that we may lack the power to 
detect a difference between the adjusted risk ratios after we adjusted for the effect of age, partner 
number, education, time on study, MACS visit sequence, and repeated observations, even if such a 
difference exists. 
These analyses are important because, unlike many prior studies, we have sufficient power to detect 
complex relationships between HPV infection and important clinical exposures: smoking, HIV 
infection and historical EGWs. Our findings are consistent with and extend the findings of other 
investigators that smoking increases the risk for EGWs caused by non-oncogenic HPV infection, and 
our data suggest but cannot confirm that these factors may similarly affect lesions attributable to 
oncogenic genital HPV infections. Additionally, HIV and the consequent decline of immunity enhance 
this risk further as do historical EGWs. Most important, these relations persisted even after we 
controlled for the effect of the number of insertive and receptive sexual partners each man reported, 
age, education, study site, and time on study. We should continue to counsel patients to stop smoking. 
Although we found that each receptive anal intercourse partnership increased risk for new EGWs by a 
modest 2%, counseling should nonetheless include a recommendation to decrease the lifetime number 
of sexual partners to avoid exposure to these and other sexually transmitted pathogens, including HIV. 
Additionally, these data suggest HIV-infected men should be counseled about their enhanced risk for 
EGWs and other possible HPV-related clinical manifestations that are exacerbated further by tobacco 
smoking. Future studies should explore these relationships with regard to intra-anal infection and anal Int. J. Environ. Res. Public Health 2009, 6   
 
1225
intraepithelial neoplasias, and determine whether pharmacological immune reconstitution decreases 
risk for EGWs and other HPV-related diseases within the context of HIV infection. 
 
4. Materials and Methods 
 
Setting and study group: The Multicenter AIDS Cohort Study (MACS) is a natural history of disease 
study that has been described extensively elsewhere [81,82]. Briefly, a total of 5,622 asymptomatic 
men thought at-risk for AIDS were recruited at four geographic locations between March 1984 and 
April 1985 [81,82]. At the first MACS visit, men were 37.7 (±7.7) years of age on average; most had 
completed four years of college, and most reported Caucasian race/ethnicity [81,82]. In 1985, 1,808 
men were identified as infected with HIV at their first MACS visit (prevalent positive) when an 
antibody test became available, and another 559 men have tested positive for HIV (seroconverters) 
since enrollment. 
Self- and interviewer-guided questionnaires were administered semi-annually, approximately 6 
months apart, to collect demographic, treatment, medication and behavioral characteristics. Self-report 
for EGWs has been collected consistently throughout the first sixteen MACS visits. Additionally, 
trained MACS examiners performed physical examinations at each visit using bright light and 
magnification where needed. Warts at the anal verge and on perianal tissues were recorded separately 
from warts on the penis, scrotum and other surrounding genital surfaces. Laboratory data collected at 
each visit routinely include white blood cell counts and measurements of lymphocyte subsets, e.g., 
CD4+ cell counts. 
Although a consistent core of variables has been collected throughout, the number of different types 
of sexual partners and specific behaviors were not linked to individual relationships through visit 
seven. Sexual behavior variables were modified beginning at visit eight to better describe behaviors for 
individual relationships. Nonetheless, the number of sex acts for specific partners could not be 
estimated from these data; only the number of partnerships in each six month period could be 
determined. HIV-treatments that may confound our data were infrequently used during the first sixteen 
MACS visits. Monotherapy, using nucleoside reverse transcriptase inhibitors alone, was first reported 
by MACS men as treatment for HIV infection after 1987. For the eighth through 16th visits, no men 
reported simultaneous administration of more than one antiretroviral medication, including protease 
inhibitors. More important, the MACS cohort was censored administratively after visit 16, and the 
scope of data collected for some HIV-uninfected men was limited. Most characteristics of interest 
varied over time, including the study outcome variable, and were updated for these analyses with each 
study visit (index visit). 
 
Study sample: To maximize power and minimize bias, only data from visits eight to 16 were included 
in these analyses. The study sample was limited to men who reported no EGWs over the prior six 
months and were not found to have EGWs by a MACS examiner at their first study visit of the risk 
period. Additionally, eligible subjects must have completed at least four study visits. A total of 3,030 
men completed 22,951 study visits; however, data for 195 men who either reported or were diagnosed 
with EGWs at their first study visit were excluded from the risk set. Thus, our analyses were limited to 
data collected at 21,519 semi-annual visits from 2,835 MACS men. Int. J. Environ. Res. Public Health 2009, 6   
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Study endpoint: Men included in these analyses began the study period free of symptomatic EGWs, 
reported no episodes of warts during the prior six months, and completed four or more study visits 
during the study period. Two groups of men met the study endpoint: men with examiner-diagnosed 
warts on the penis, perigenital, perianal tissues and on the anal verge; and men who self-reported one 
or more occurrences of EGWs during the six months preceding each study visit. Also, to examine the 
sensitivity of this classification scheme, additional sub-analyses were performed where men were 
classified as unaffected if they reported one or more occurrences of EGWs during the six months 
preceding each study visit, but were not found to have warts by an examiner. 
 
Exposures of interest: Four characteristics were of primary interest in these analyses: tobacco use, 
historical evidence of EGWs, HIV serostatus and, for HIV-infected men, the CD4+ cell count. MACS 
men self-report tobacco consumption at each semi-annual study visit. For these analyses, men were 
classified dichotomously as tobacco-users or not at each study visit, reflecting an assumption that 
tobacco exposure has a short-term effect on risk for new episodes of EGWs. Over the risk period, 
objective laboratory data summarizing HIV infection status and CD4+ cell counts among those 
infected, and self-report for tobacco smoking were evaluated and updated at each study visit. 
 
Other Covariates of Interest: All eligible men began the risk period asymptomatic for EGWs; thus, to 
characterize the effect of prior warts on new occurrences, we classified men in three ways. First, those 
who began the risk period without ever having reported or having been diagnosed with EGWs by a 
MACS examiner were classified as having no historical episodes of EGWs at the first study visit. 
Second, men who were diagnosed at the first through seventh MACS visits with EGWs, reported 
having been diagnosed by a clinician with EGWs between study visits, or reported any history of 
genital warts at the first MACS visit were classified as having historical episodes of EGWs. Last, men 
who developed warts during the study period reentered the risk set and were subsequently classified as 
having a prior history of EGWs. Accordingly, both incident EGWs and prior history of EGWs were 
treated as time-dependent covariates and were updated at every study visit. Several additional 
characteristics of interest were time on study and number of receptive and insertive anal sex 
partnerships, which were abstracted from the data. Additionally, age, education and study site were 
summarized from the first MACS visit data. For these analyses, age for each man was centered around 
the mean age of the study group and entered as a continuous variable. Additionally, men who reported 
12 or fewer years of education, men with some college, men with baccalaureate degrees, and men with 
some post-graduate education were compared to men who reported achieving post-graduate degrees. 
 
Analyses: Tabular and descriptive statistics were used to explore differences between men with and 
without historical evidence of prior EGWs, smokers and non-smokers, men with and without HIV 
infection, and among the infected, five levels of CD4+ cell counts. Inter-current and historical 
occurrences of EGWs were updated with each study visit. CD4+ cell count groupings were updated at 
each study visit and men with 850 or more cells/mm
3 were compared to men with 500 to 849, 350 to 
499, 200 to 349, and fewer than 200 cells/mm
3. Our prior analyses suggest sexual behaviors may 
confound our estimates because they are associated with both the occurrence of new and historical anal 
warts, smoking, and HIV infection characteristics [19,83]. Also, to control for confounding of sexual Int. J. Environ. Res. Public Health 2009, 6   
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behaviors, the number of receptive and insertive anal partners were each treated as a continuous 
variable and included in our multivariate analyses. Age and time on study (i.e., number of days 
between each man’s first MACS visit and the index study visit) were included as continuous variables 
in multivariable models. Men with post-graduate education were compared to men with fewer than 12 
years of education, high school graduates, one or more years of college education but no degree, and 
men who completed four years of college. 
A series of logistic regression models were built to examine the crude risk of being diagnosed with 
EGWs. Subsequently, a series of generalized linear models with repeated binary responses were 
developed to determine whether
 diagnosis of EGWs was
 affected by the covariates of interest. The
 
SAS GENMOD procedure was
  used for these analyses [84].
  Models were fit
  by a generalized 
estimating
 equation; fits of
 various models were evaluated
 by the deviance statistic
 and were rejected
 or 
not by using
 a 0.05 level of
 significance [84]. 
A series of five multivariate models were tested to estimate risk ratios and provide a comparison of 
the influence that some covariates had upon the risk for being diagnosed with EGWs (Table 1). Our 
final model estimated the relative risk of developing EGWs at any study visit as a function of smoking, 
historical EGWs, HIV infection status, and, for HIV-infected men, CD4+ cell counts. Multivariate 
models adjusted for age, the number of receptive and insertive anal intercourse partners reported for 
the six-months preceding each study visit (partner number), education, and time on study. We 
constructed an additive model and then assessed the effect of interaction between smoking, history of 
EGWs, and HIV infection, including CD4+ cell counts for HIV-infected men. The number of partners 
men reported was also included in our final analysis. Overall, the model fit well. Additionally, the 
deviance statistic suggested that the purely multiplicative model was superior (deviance statistic for 
full multiplicative model versus additive model, X
2 = 33.5, p = 0.01) [84]. 
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